Notably, ABR-238901, a small molecule that inhibits the interaction of S100A9 with its receptors, decreases the secretion of IL-6 and IL-10 from MDSCs, inhibits the neoangiogenic process, but would not have shown satisfactory efficacy in reducing tumour progression. Here, IL6 is linked to neoplasm.